Abstract 262P
Background
Gestational trophoblastic tumors (GTTs) are the malignant forms of gestational trophoblastic diseases. They always follow a pregnancy, most often molar. The diagnosis of TTG is based on an abnormal course of HCG (chorionic gonadotropin hormone) and / or signs of ultrasound invasion and/or histological confirmation.
Methods
it is a retrospective study of 29 cases of GTT collected at the medical oncology department of Hassan II University Hospital-Fez, over a period of 7 years from January 2010 to December 2016.
Results
The average age was 35 years old. Sixty-five percent (65%) of our patients were pauciparous. The causal pregnancy was in 83% of cases a molar pregnancy. The staging of patients revealed pulmonary metastases in 67% of cases, liver in 19% of cases, renal in 7% of cases and cerebral in 7% of cases. Nine patients (31 %) underwent hysterectomy, with postoperative chemotherapy for 8 patients. Fifty-two percent (52%) were at high risk while 48% were low risk. Low risk patients received methotrexate-based monochemotherapy, and HCG hormone became negative after an average of 6.5 cycles. High risk patients received a polychemotherapy with differents protocols used; EMA-CO, BEP, or Cisplatin-Etoposid-MTX protocol, after an average of 3.28 cycles, the HCG hormone became negative. Eighty-six percent of our patients benefited from clinical and biological monitoring. The evolution of our patients was marked by a complete clinical and biological remission in 89.65% of patients, after an average of 12 weeks. The median survival was 76.4 ± 2.7 months, after a median follow-up of 29.78 months.
Conclusions
Malignant gestational trophoblastic tumors are a rare and challenging disease with heavy psychosocial impact hat affect the young woman who has not only had a pregnancy loss but also may be faced with a life-threatening illness. More understanding of risk factors, carcinogenesis and management is required to improve the outcome of thes patients. larger studies are still needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract